Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

G Waguespack, Steven; Drilon, Alexander; J Lin, Jessica; S Brose, Marcia; McDermott, Ray; Almubarak, Mohammed; Bauman, Jessica; Casanova, Michela; Krishnamurthy, Anuradha; Kummar, Shivaani; Leyvraz, Serge; Oh, Do-Youn; Park, Keunchil; Sohal, Davendra; Sherman, Eric; Norenberg, Ricarda; D Silvertown, Josh; Brega, Nicoletta; S Hong, David; E Cabanillas, Maria

doi:10.1530/eje-21-1259

Public

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Published in European Journal of Endocrinology • Mar 25, 2022

Authors:

Steven G Waguespack

Alexander Drilon

Jessica J Lin

Abstract

Objective: Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). Methods: We pooled...

Subject

Trk receptor

Medicine

Thyroid carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!